Poseida Therapeutics, Inc.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $25 M | No. 5 | $10 to $50 million | equity | SEC | |
| Mar 2019 | $142 M | No. 4 | $50 to $250 million | equity | SEC | |
| Mar 2018 | $31 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jul 2017 | $11 M | No. 2 | $10 to $50 million | equity | SEC | |
| Dec 2015 | $23 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Poseida Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2023
That is all the official record says: Poseida Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Malin Corp PLC | Company | not stated | not stated | Held Series A, A-1, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Malin Life Sciences Holdings Ltd | Company | not stated | not stated | Held Series A, A-1, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Novartis AG | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Novartis Pharma AG | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 17 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brent J. Warner | Executive officer | Aug 2023 |
| Harry J. Leonhardt | Executive officer | Aug 2023 |
| Johanna M. Mylet | Executive officer | Aug 2023 |
| Kristin J. Yarema | Executive officer | Aug 2023 |
| Mark J. Gergen | Executive officer | Aug 2023 |
| Eric Ostertag | Executive officer | Apr 2019 |
| Mark Gergen | Executive officer | Apr 2019 |
| Matthew Spear | Executive officer | Apr 2019 |
| Nishan de Silva | Executive officer | Aug 2017 |
| Charles M. Baum | Director | Aug 2023 |
| Cynthia M. Collins | Director | Aug 2023 |
| John B. Schmid | Director | Aug 2023 |
| Luke M. Corning | Director | Aug 2023 |
| Marcea B. Lloyd | Director | Aug 2023 |
| Mark J. Gergen | Director | Aug 2023 |
| Rafael J. Amado | Director | Aug 2023 |
| Catherine J. Mackey | Director | Apr 2019 |
| David Hirsch | Director | Apr 2019 |
| Eric Ostertag | Director | Apr 2019 |
| John J. Schmid | Director | Apr 2019 |
| Marcea Bland Lloyd | Director | Apr 2019 |
| Mark Gergen | Director | Apr 2019 |
| Noah J. Berkowitz | Director | Apr 2019 |
| Sean J. Murphy | Director | Apr 2019 |
| Adrian Howd | Director | Apr 2018 |
| Lars Ekman | Director | Aug 2017 |
| Nishan de Silva | Director | Aug 2017 |
| Robert Lyons | Director | Aug 2017 |